Halozyme Therapeutics (HALO) Cost of Revenue (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cost of Revenue data on file, last reported at $79.2 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 63.7% year-over-year to $79.2 million in Q1 2026; TTM through Mar 2026 was $259.6 million, a 44.64% increase from a year earlier, with the FY2025 full-year figure at $228.8 million, up 43.51% from the prior year.
• Cost of Revenue for Q1 2026 stood at $79.2 million, up from $78.8 million in the prior quarter.
• Over the last five years, Cost of Revenue for HALO reached as high as $79.2 million in Q1 2026 and fell as low as $15.9 million in Q1 2022.
• Historically, Cost of Revenue has averaged $47.0 million across 5 years, with a median of $47.3 million in 2022.
• Across the five-year window, Cost of Revenue jumped 154.55% in 2022 and fell 20.9% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $42.1 million in 2022, then rose by 24.16% to $52.3 million in 2023, then dropped by 19.59% to $42.1 million in 2024, then jumped by 87.3% to $78.8 million in 2025, then gained by 0.59% to $79.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $79.2 million in Q1 2026, $78.8 million in Q4 2025, and $55.2 million in Q3 2025.